Tag: CPI-613

Atlantic Health System Leads Phase 1 Study on CPI-613® (Devimistat), First-in-Class Treatment for Pancreatic Cancer to be Presented at American Society of Clinical Oncology (ASCO) 2020

sarah JonasResearch Results

Dr. Alistar has pioneered the use of CPI-613® (devimistat), a unique first-in-class treatment for locally advanced or metastatic pancreatic cancer, in combination with two chemotherapy drugs. Devimistat uniquely targets enzymes involved in cancer cell metabolism, against pancreatic cancer. The study’s efficacy data suggest devimistat has synergy with chemotherapy.The current study was funded by the drug’s manufacturer, New Jersey-based Rafael Pharmaceuticals and by Atlantic Health System.